Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States.
High growth potential with adequate balance sheet.
Share Price & News
How has Pacira BioSciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PCRX's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: PCRX exceeded the US Pharmaceuticals industry which returned 7.7% over the past year.
Return vs Market: PCRX matched the US Market which returned 9.2% over the past year.
Price Volatility Vs. Market
How volatile is Pacira BioSciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StHow Much Did Pacira BioSciences, Inc.'s (NASDAQ:PCRX) CEO Pocket Last Year?
1 month ago | Simply Wall StShould You Be Concerned About Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Historical Volatility?
2 months ago | Simply Wall StRoy Winston Just Bought Shares In Pacira BioSciences, Inc. (NASDAQ:PCRX)
Is Pacira BioSciences undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PCRX ($46.12) is trading below our estimate of fair value ($104.71)
Significantly Below Fair Value: PCRX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PCRX is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: PCRX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PCRX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PCRX is overvalued based on its PB Ratio (5.2x) compared to the US Pharmaceuticals industry average (3.6x).
How is Pacira BioSciences forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PCRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: PCRX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PCRX's is expected to become profitable in the next 3 years.
Revenue vs Market: PCRX's revenue (13.9% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: PCRX's revenue (13.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PCRX's Return on Equity is forecast to be high in 3 years time (29.4%)
How has Pacira BioSciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PCRX is currently unprofitable.
Growing Profit Margin: PCRX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PCRX is unprofitable, but has reduced losses over the past 5 years at a rate of 6.6% per year.
Accelerating Growth: Unable to compare PCRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PCRX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.5%).
Return on Equity
High ROE: PCRX has a negative Return on Equity (-0.022%), as it is currently unprofitable.
How is Pacira BioSciences's financial position?
Financial Position Analysis
Short Term Liabilities: PCRX's short term assets ($431.6M) exceed its short term liabilities ($80.3M).
Long Term Liabilities: PCRX's short term assets ($431.6M) exceed its long term liabilities ($367.0M).
Debt to Equity History and Analysis
Debt Level: PCRX's debt to equity ratio (82.9%) is considered high.
Reducing Debt: PCRX's debt to equity ratio has increased from 56.5% to 82.9% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable PCRX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: PCRX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 62.2% per year.
What is Pacira BioSciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PCRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PCRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PCRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PCRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PCRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dave Stack (69yo)
Mr. David M. Stack, also known as Dave, has been the Chief Executive Officer of Pacira Pharmaceuticals Inc. Since 2007, Mr. Stack has served as Chief Executive Officer and Chairman of Pacira BioSciences, I ...
CEO Compensation Analysis
Compensation vs Market: Dave's total compensation ($USD5.81M) is about average for companies of similar size in the US market ($USD4.72M).
Compensation vs Earnings: Dave's compensation has been consistent with company performance over the past year.
|Chairman & CEO||12.58yrs||US$5.81m||0.26% $5.0m|
|Chief Financial Officer||4.08yrs||US$1.39m||0.0091% $175.8k|
|Chief Administrative Officer & Secretary||5.67yrs||US$1.69m||no data|
|Chief Clinical Officer||1.83yrs||US$1.61m||0.032% $620.3k|
|Principal Accounting Officer & VP of Finance||8.25yrs||US$288.82k||0.010% $203.4k|
|Chief Technical Officer||1.5yrs||no data||0.0038% $74.6k|
|Head of Investor Relations||no data||no data||no data|
|Vice President of Human Resources||4.92yrs||no data||no data|
|Senior Vice President of Alliance Management||4.17yrs||US$1.92m||no data|
Experienced Management: PCRX's management team is considered experienced (4.2 years average tenure).
|Chairman & CEO||12.58yrs||US$5.81m||0.26% $5.0m|
|Independent Director||9yrs||US$445.95k||0.011% $213.5k|
|Independent Lead Director||7yrs||US$458.95k||0.0065% $126.7k|
|Independent Director||12yrs||US$421.95k||0.13% $2.5m|
|Independent Director||13.5yrs||no data||no data|
|Independent Director||12.92yrs||US$442.95k||0.029% $570.2k|
|Independent Director||7yrs||US$430.95k||0.024% $474.0k|
|Independent Director||6.25yrs||US$424.95k||0.013% $259.5k|
|Independent Director||3yrs||US$424.95k||0.0014% $26.8k|
Experienced Board: PCRX's board of directors are considered experienced (7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PCRX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Pacira BioSciences, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Pacira BioSciences, Inc.
- Ticker: PCRX
- Exchange: NasdaqGS
- Founded: 2006
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.943b
- Shares outstanding: 42.12m
- Website: https://www.pacira.com
Number of Employees
- Pacira BioSciences, Inc.
- 5 Sylvan Way
- Suite 300
- New Jersey
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PCRX||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Feb 2011|
|82P||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 2011|
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company has collaboration with Aetna. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/04 13:48|
|End of Day Share Price||2020/06/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.